Information Provided By: 
Fly News Breaks for May 25, 2017
PBYI
May 25, 2017 | 05:39 EDT
Citi analyst Yigal Nochomovitz raised his price target for Puma Biotechnology to $105 after an FDA panel voted 12-4 in favor of the company's breast cancer treatment neratinib. Upside on takeout speculation could drive shares even higher, Nochomovitz tells investors in a research note. He keeps a Buy rating on Puma. The stock closed yesterday up 30%, or $17.15, to $74.95.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
